Country: United States
Language: English
Source: NLM (National Library of Medicine)
BIVALIRUDIN (UNII: TN9BEX005G) (BIVALIRUDIN - UNII:TN9BEX005G)
Sandoz Inc
BIVALIRUDIN
BIVALIRUDIN 250 mg
INTRAVENOUS
PRESCRIPTION DRUG
Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Bivalirudin is contraindicated in patients with: Risk Summary There are no data available on use of bivalirudin in pregnant women to inform a drug-associated risk of adverse developmental outcomes. Reproduction studies in rats and rabbits administered subcutaneously doses up to 1.6 times and 3.2 times the maximum recommended human dose (MRHD) of 15 mg/kg/day based on body surface area (BSA) during organogenesis, respectively, revealed no evidence of fetal harm. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage
Bivalirudin for injection is supplied as a sterile, lyophilized powder in single-dose, glass vials. Each vial contains 250 mg of bivalirudin equivalent to an average of 275 mg of bivalirudin trifluoroacetate*. *The range of bivalirudin trifluoroacetate is 270 to 280 mg based on a range of trifluoroacetic acid composition of 1.7 to 2.6 equivalents. NDC 0781-9158-95 – Package of 10 – 250 mg Single-Dose Vials Store Bivalirudin dosage units at 20° to 25°C (68° to 77°F); excursions to 15° to 30°C permitted [see USP Controlled Room Temperature].
New Drug Application Authorized Generic
BIVALIRUDIN- BIVALIRUDIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION SANDOZ INC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BIVALIRUDIN FOR INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BIVALIRUDIN FOR INJECTION. BIVALIRUDIN FOR INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 2000 INDICATIONS AND USAGE Bivalirudin for injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia (HIT) or heparin- induced thrombocytopenia and thrombosis syndrome (HITTS).(1) DOSAGE AND ADMINISTRATION • • DOSAGE FORMS AND STRENGTHS For injection: 250 mg of bivalirudin as a lyophilized powder in a single-dose vial for reconstitution. (3) CONTRAINDICATIONS • • WARNINGS AND PRECAUTIONS • • • ADVERSE REACTIONS Most common adverse reaction (>2%) was bleeding. (6.1) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT SANDOZ INC. AT 1-800-525-8747 OR FDA AT 1-800-FDA- 1088 OR WWW.FDA.GOV/MEDWATCH. DRUG INTERACTIONS Heparin, warfarin, thrombolytics, or GPIs: Increased major bleeding risk with concomitant use. (7) USE IN SPECIFIC POPULATIONS • • SEE 17 FOR PATIENT COUNSELING INFORMATION. REVISED: 9/2019 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION The recommended dosage is a 0.75 mg/kg intravenous bolus dose followed immediately by a 1.75 mg/kg/h intravenous infusion for the duration of the procedure. Five minutes after the bolus dose has been administered, an activated clotting time (ACT) should be performed and an additional bolus dose of 0.3 mg/kg should be given if ne e de d. Extending duration of infusion post-procedure up to 4 hours should be considered in patients with ST segment elevation MI (STEMI). (2.1) Active major bleeding (4) Hypersensitivity to bivalirudin or its components (4) Bleeding Events: Bivalirudin increases the risk of ble Read the complete document